| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|---|---|---|---|---|---|---|---|
| Q3 2024 | 52 | $581M | +$28.8M | -$144M | -$115M | C, MRK, BP, NYCB, BAYRY | 13F-HR | 11/13/2024, 11:41 AM |
| Q2 2024 | 51 | $595M | +$54M | -$71.2M | -$17.2M | C, MRK, BP, GSK, NYCB | 13F-HR | 8/14/2024, 03:14 PM |
| Q1 2024 | 52 | $674M | +$59.4M | -$24.5M | +$34.9M | AGO, MRK, C, BP, GSK | 13F-HR | 5/15/2024, 02:14 PM |
| Q4 2023 | 42 | $635M | +$7M | -$19.4M | -$12.4M | AGO, MRK, NYCB, C, BP | 13F-HR | 2/13/2024, 10:33 AM |
| Q3 2023 | 43 | $641M | +$3.63M | -$13.4M | -$9.74M | NYCB, BP, MRK, AGO, PTEN | 13F-HR | 11/13/2023, 04:42 PM |
| Q2 2023 | 43 | $682M | +$2.39M | -$23.6M | -$21.2M | MRK, NYCB, BP, BMY, AGO | 13F-HR | 8/9/2023, 02:59 PM |
| Q1 2023 | 45 | $695M | +$8.08M | -$27M | -$18.9M | BP, MRK, BMY, NYCB, AGO | 13F-HR | 5/12/2023, 10:36 AM |
| Q4 2022 | 45 | $760M | +$3.98M | -$8.77M | -$4.79M | AGO, MRK, BP, PTEN, BMY | 13F-HR | 2/15/2023, 10:56 AM |
| Q3 2022 | 45 | $642M | +$14.2M | -$13.6M | +$591K | BMY, BP, AGO, MRK, PTEN | 13F-HR | 11/15/2022, 10:02 AM |
| Q2 2022 | 45 | $743M | +$21.1M | -$17.7M | +$3.43M | PTEN, AGO, BMY, MRK, BP | 13F-HR | 8/10/2022, 12:36 PM |
| Q1 2022 | 46 | $788M | +$142M | -$153M | -$11M | PTEN, AGO, MBI, BMY, BP | 13F-HR | 5/2/2022, 02:12 PM |
| Q4 2021 | 43 | $727M | +$17.3M | -$1.89M | +$15.4M | MBI, AGO, GSK, PFE, BP | 13F-HR | 1/25/2022, 09:25 AM |
| Q3 2021 | 43 | $710M | +$22.1M | -$6.84M | +$15.3M | AGO, MBI, BP, NYCB, C | 13F-HR | 11/1/2021, 10:31 AM |
| Q2 2021 | 43 | $698M | +$26.9M | -$48.3M | -$21.4M | AGO, C, BMY, PTEN, BP | 13F-HR | 8/4/2021, 10:17 AM |
| Q1 2021 | 42 | $646M | +$5.5M | -$59M | -$53.5M | AGO, C, NYCB, BMY, MBI | 13F-HR | 5/7/2021, 02:09 PM |
| Q4 2020 | 42 | $573M | +$3.74M | -$53.7M | -$50M | BMY, C, AGO, GSK, NYCB | 13F-HR | 2/11/2021, 10:45 AM |
| Q3 2020 | 42 | $528M | +$6.62M | -$45.4M | -$38.7M | BMY, GSK, NYCB, C, AGO | 13F-HR | 11/6/2020, 09:36 AM |
| Q2 2020 | 47 | $592M | +$18.2M | -$25.4M | -$7.22M | GSK, BMY, NYCB, C, BP | 13F-HR | 8/3/2020, 02:43 PM |
| Q1 2020 | 48 | $547M | +$1.75M | -$25.6M | -$23.9M | GSK, BMY, NYCB, BP, C | 13F-HR | 5/11/2020, 10:16 AM |
| Q4 2019 | 47 | $824M | +$2.05M | -$24.6M | -$22.5M | C, AGO, GSK, BMY, NYCB | 13F-HR | 1/27/2020, 01:41 PM |
| Q3 2019 | 48 | $707M | +$14.9M | -$11.9M | +$2.97M | C, AGO, NYCB, GSK, BP | Restatement | 11/5/2019, 10:40 AM |
| Q2 2019 | 44 | $710M | +$169M | -$7.64M | +$161M | C, BP, AGO, GSK, SEB | 13F-HR | 8/5/2019, 11:27 AM |
| Q1 2019 | 32 | $640M | +$25.2M | -$43.7M | -$18.5M | BP, C, AGO, GSK, NYCB | 13F-HR | 5/6/2019, 10:06 AM |
| Q4 2018 | 31 | $555M | +$7.99M | -$12.5M | -$4.47M | BP, C, AGO, GSK, NYCB | 13F-HR | 1/29/2019, 02:33 PM |
| Q3 2018 | 31 | $651M | +$14.8M | -$16.9M | -$2.16M | C, BP, AGO, BB, GSK | 13F-HR | 10/30/2018, 02:36 PM |
| Q2 2018 | 31 | $628M | +$12.4M | -$16.6M | -$4.18M | BP, C, GSK, NYT, AGO | 13F-HR | 8/6/2018, 10:09 AM |
| Q1 2018 | 31 | $628M | +$16M | -$27M | -$10.9M | C, BP, NYT, BB, GSK | 13F-HR | 5/1/2018, 03:04 PM |
| Q4 2017 | 31 | $637M | +$16.7M | -$16.8M | -$119K | C, BP, NYT, BB, GSK | 13F-HR | 1/25/2018, 02:34 PM |
| Q3 2017 | 34 | $639M | +$24.6M | -$40.4M | -$15.8M | C, NYT, BP, BB, GSK | Restatement | 11/7/2017, 12:21 PM |
| Q2 2017 | 34 | $656M | +$24.7M | -$28.6M | -$3.87M | C, NYT, BP, GSK, BB | 13F-HR | 8/8/2017, 11:52 AM |
| Q1 2017 | 35 | $580M | +$27.7M | -$28.7M | -$983K | C, NYT, BP, GSK, HOLX | 13F-HR | 5/8/2017, 01:58 PM |
| Q4 2016 | 35 | $592M | +$32.7M | -$45.7M | -$13M | C, NYT, BP, HOLX, MBI | 13F-HR | 1/31/2017, 02:23 PM |
| Q3 2016 | 35 | $552M | +$15.9M | -$17.2M | -$1.23M | C, HOLX, BP, NYT, BB | 13F-HR | 11/1/2016, 10:03 AM |
| Q2 2016 | 37 | $517M | +$11.6M | -$29.3M | -$17.7M | C, NYT, BP, HOLX, PFE | 13F-HR | 8/9/2016, 01:27 PM |
| Q1 2016 | 37 | $534M | +$9.21M | -$19.8M | -$10.6M | NYT, C, HOLX, NYCB, PFE | 13F-HR | 5/9/2016, 10:58 AM |
| Q4 2015 | 38 | $560M | +$9.66M | -$6.83M | +$2.83M | C, NYT, HOLX, PFE, NYCB | 13F-HR | 2/8/2016, 10:02 AM |
| Q3 2015 | 38 | $540M | +$20.5M | -$19.1M | +$1.35M | C, HOLX, PFE, NYCB, NYT | 13F-HR | 11/9/2015, 12:11 PM |
| Q2 2015 | 40 | $593M | +$17.9M | -$27.3M | -$9.42M | C, PFE, NYCB, NYT, HOLX | 13F-HR | 7/28/2015, 10:12 AM |
| Q1 2015 | 42 | $592M | +$8.13M | -$33.3M | -$25.1M | PFE, C, NYT, NYCB, HOLX | 13F-HR | 5/6/2015, 09:33 AM |
| Q4 2014 | 44 | $568M | +$8.55M | -$40.3M | -$31.7M | C, PFE, NYT, NYCB, SEB | 13F-HR | 2/3/2015, 10:54 AM |
| Q3 2014 | 44 | $615M | +$3.7M | -$38.8M | -$35.1M | C, PFE, NYCB, NYT, HOLX | 13F-HR | 11/6/2014, 10:45 AM |
| Q2 2014 | 43 | $687M | +$67.8M | -$51.1M | +$16.7M | NYT, C, PFE, NYCB, BP | 13F-HR | 8/6/2014, 02:37 PM |
| Q1 2014 | 42 | $701M | +$93.6M | -$4.58M | +$89.1M | NYT, PFE, NYCB, C, ORI | 13F-HR | 5/7/2014, 01:56 PM |
| Q4 2013 | 42 | $551M | $0 | $0 | NYT, PFE, C, NYCB, ORI | 13F-HR | 2/4/2014, 01:44 PM |